Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Advanced Technologies » HAD-8431117
  • Global Companion Diagnostics Market- Technologies, Market share and Industry Forecast to 2024

  • Publish: November 2017 | Report Code: HAD-8431117

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

Companion diagnostic tests are used to recognize suitable patients for applying specific drugs and monitoring the prognosis of drug effects on the disease. The global companion diagnostics market is expected to reach from $2.17 billion in 2016 to $6.51 billion by 2023, at a CAGR of 20.1% for the forecasted period. The driving factor for the growth companion diagnostic market is the increasing lung cancer cases, rising need for personalized medicines, growing number of genetic testing, and regulatory guidelines framework that support the companion diagnostics market. Technological advancements have changed the disease treatment method a lot. Companion diagnostics is expanding by growing requirement for better personalized patient treatment. This gives positive assurance about treatment to both healthcare providers and patients. Contrary to traditional treatment procedure it is more effective. Oncology area is having major impact of companion diagnostic therapy. Many of the companion diagnostics tests can be given approval for single drug as scientific knowledge advances with the practical application for the treatment. This increases the number of treatment procedures. However, latest technology related cost acts as a barrier for the growth of global companion diagnostics market.

The key driver for global companion diagnostic market is an increase in research & development of drugs, which require a corresponding companion diagnostic. Companion diagnostic is gaining importance in personalized treatment medicine and drug discovery. Patient personal molecular profile are determined using this. That helps in deciding the therapy used for treatment of patient. For specific types of cancer companion diagnostics are available in the market, and many are under clinical trials and development. By determining companion biomarker, Companion diagnostics are also used in drug development process. Lack of awareness and skilled professionals in the developing countries is adversely affecting the growth of companion diagnostics.

Source: OBRC Analysis.

The methodology for research used in companion diagnostics market.  The base year for estimating market is 2015 and forecasted period is 2016-2023.

The report on global companion diagnostics market is segmented on basis of products and services, end users, technology and indication.

Product and services are classified into:

  • Assay kits and reagents market
  • Software and service market



The technology for global companion diagnostics market includes:

  • In situ hybridization market
  • Polymerase chain reaction market
  • Immunohistochemistry market
  • Next generation sequencing market
  • Other technologies market






Global companion diagnostics market, by end users is classified as:

  • Pharmaceutical and biopharmaceutical companies market
  • Reference laboratories market
  • Other end user market




The indication for global companion diagnostics market includes:

  • Oncology market
  • Neurology market
  • Infectious diseases market
  • Other indications market





The companion diagnostics market report has been geographically segmented in:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan, RoAPAC)
  • Europe (UK, France, Germany, RoE)
  • Rest of World





North America is dominating the global companion diagnostics market. Structured regulatory framework, large number of drug development activities, and launch of several companion diagnostic products are the key reasons of the growth of this region. The Asia-Pacific is expected to witness the highest CAGR during the forecast period. Growing need of tailored therapeutics for the elderly population, increasing number of diagnostic laboratories and hospitals, and growing life-threatening diseases are driving the growth for companion diagnostics market in this region. Rest of the world holds immense potential for the growth as there are untapped opportunities in companion diagnostics market.

Companion diagnostics market is segmented into products & and services, technology, indication, end user, and regions. In product and service region, the assay kits & and reagents segment is dominating the market for the forecasted. Consisting its wide range of applications platforms as PCR, NGS, IHC, and ISH. On the basis of technology, the polymerase chain reaction segment held the largest share in 2016. Ease of use and easy availability of kits and reagents in minimal times in comparison of other technologies are leading the segment. On the basis of indication, companion diagnostic market is classified into neurology, oncology, infectious diseases, and other indications (which consist cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology is the fastest growing segment and is dominating the market. This is primarily attributing to growing incidence of cancer, enhanced focus on cancer research, are key factor for the growth. On the basis of technology market is segmented into in situ hybridization, polymerase chain reaction, immunohistochemistry market, next generation sequencing market and other technologies. On the basis of end user market is classified into pharmaceutical and biopharmaceutical companies, reference laboratories market, other end user market.  The pharmaceutical and biopharmaceutical companies segment is dominating the market for the forecasted period.

The major market players of the global companion diagnostics market are:

  • Qiagen n.v. (Netherland)
  • Thermo fisher scientific Inc. (US)
  • Myriad genetics, Inc. (US)
  • Sysmex corporation (Japan)
  • Genomic health, Inc. (US)
  • And others







These companies are using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, merger & acquisition is the key strategy adopted by the companies in the companion diagnostics market. On Aug. 29, 2017 Thermo Fisher Scientific Inc. acquired Patheon with the aim to become leader in  clinical trials services and bio production technologies. To provides better solutions to pharmaceutical and biotech customers. This acquisition create the profit of approx $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. In August 2017, AstraZeneca along with US biology and technology company Berg launched new drugs for the treatment of Parkinson’s disease and also for treating other neurological disorders, using artificial intelligence. This product launch cost more than $2.5billion.

The report covers detailed analysis of companies which comprises overview, SCOT analysis, product portfolio, strategic initiative, strategic analysis, competitive landscape and market share analysis in voice communication equipment market.

Key reason to buy the report:

  • The Global Companion diagnostics Market- Growth, Share, Opportunities, and Competitive Analysis, 2016 – 2023” offers strategic insights into the global companion diagnostics market along with the market size and estimates for the duration 2016 to 2023..
  • The report includes market estimation, forecast and analysis for the year 2016-2023
  • Report includes detailed analysis of different segments such as equipment product and applications of companion diagnostics market.
  • Identify and understand the strength, opportunities, challenges and threat of the companion diagnostics market.
  • Covers details analysis of Porters 5 force model and other strategic models and also covers revenues, market share analysis, and competitive landscape analysis of major players of companion diagnostics market.
  • Detailed analysis of various the regulatory policies which are affecting the global companion diagnostics market.
  • Current and future market trends to justify the forthcoming attractive markets within the companion diagnostics market
  • In-depth competitive environment analysis









How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global companion diagnostics market offers detailed analysis of strategic models such as investment vs. adoption model, see saw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the voice communication equipment market, with giving extensive SCOT analysis of key companies. 

Key findings of the global companion diagnostics market:

  • North America held highest revenue share in 2016.
  • Merger & Acquisition is the key strategy adopted by players of companion diagnostics market.  
  • Asia Pacific is the fastest growing region in the global companion diagnostics market.
  • Oncology is the fastest growing segment and held the largest share in the market. 
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL COMPANION DIAGNOSTIC MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. TOTAL MARKET ANALYSIS
2.4.1. TOP 5 FINDINGS
2.4.2. TOP 5 OPPORTUNITY MARKETS
2.4.3. TOP 5 COMPANIES
2.4.4. TOP 3 COMPETITIVE STRATEGIES
2.5. ESTIMATION ANALYSIS
2.6. STRATEGIC ANALYSIS
2.6.1. INVESTMENT VS. ADOPTION MODEL
2.6.2. 360-DEGREE INDUSTRY ANALYSIS
2.6.3. PORTERS 5 FORCE MODEL
2.6.4. SEE-SAW ANALYSIS
2.6.5. ROI ANALYSIS
2.6.6. GAP ANALYSIS
2.6.7. PATENT ANALYSIS
2.6.8. PRICING ANALYSIS
2.6.9. PIPELINE ANALYSIS
2.6.10. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.7. COMPETITIVE ANALYSIS
2.7.1. KEY STRATEGIES & ANALYSIS
2.7.2. MARKET SHARE ANALYSIS AND TOP MARKET ANALYSIS
2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1. IMPROVEMENTS IN REGULATORY GUIDELINES
3.1.2. GROWING NEED FOR TARGETED THERAPIES
3.1.3. RISING CANCER INCIDENCE ACROSS THE GLOBE
3.1.4. INCREASING PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS TEST DEVELOPMENT
3.2. MARKET RESTRAINTS
3.2.1. UNFAVORABLE REIMBURSEMENT SCENARIO
3.2.2. INTELLECTUAL PROPERTY RIGHTS PROTECTION ISSUES
3.3. MARKET OPPORTUNITIES 
3.3.1. INCREASING NEW INDICATION AREAS
3.3.2. INCREASING DEMAND FOR NEXT-GENERATION SEQUENCING
3.3.3. INCREASING NUMBER OF CLINICAL TRIALS
3.4. MARKET CHALLENGES 
3.4.1. PROLONGED DEVELOPMENT TIME OF COMPANION DIAGNOSTICS
3.4.2. INCREASING DURATION OF THE APPROVAL PROCESS
 
4. MARKET SEGMENTATION 
4.1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION 
4.1.5.1. GLOBAL ASSAY KITS AND REAGENTS MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL SOFTWARE AND SERVICE MARKET 
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.1.5.2.4. KEY CONCLUSIONS
4.2. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL IN SITU HYBRIDIZATION MARKET 
 
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.2.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL POLYMERASE CHAIN REACTION MARKET
 
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.2.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.2.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL NEXT GENERATION SEQUENCING MARKET
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.2.5.4.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL OTHER TECHNOLOGIES MARKET
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.2.5.5.3. KEY PLAYERS & KEY PRODUCTS 
4.2.5.5.4. KEY CONCLUSIONS
4.3. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION 
4.3.5.1. GLOBAL ONCOLOGY MARKET
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.3.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.2. GLOBAL NEUROLOGY MARKET
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.3.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.2.4. KEY CONCLUSIONS
4.3.5.3. GLOBAL INFECTIOUS DISEASES MARKET
4.3.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.3.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.3.4. KEY CONCLUSIONS
4.3.5.4. GLOBAL OTHER INDICATIONS MARKET
4.3.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.3.5.4.3. KEY PLAYERS & KEY PRODUCTS 
4.3.5.4.4. KEY CONCLUSIONS
4.4. GLOBAL COMPANION DIAGNOSTIC MARKET, BY END USER
 
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION 
4.4.5.1. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET
4.4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.4.5.1.3. KEY PLAYERS & KEY PRODUCTS 
4.4.5.1.4. KEY CONCLUSIONS
4.4.5.2. GLOBAL REFERENCE LABORATORIES MARKET 
4.4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.4.5.2.3. KEY PLAYERS & KEY PRODUCTS 
4.4.5.2.4. KEY CONCLUSION
4.4.5.3. GLOBAL OTHER END USER MARKET 
4.4.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.4.5.3.3. KEY PLAYERS & KEY PRODUCTS 
4.4.5.3.4. KEY CONCLUSION
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
 
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL COMPANION DIAGNOSTIC MARKET BY REGION 2014-2023($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. RUSSIA
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. F. HOFFMANN-LA ROCHE AG (SWITZERLAND)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. STRATEGIC INITIATIVES 
7.1.4. SCOT ANALYSIS
7.1.5. STRATEGIC ANALYSIS
7.2. AGILENT TECHNOLOGIES, INC. (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. STRATEGIC INITIATIVES 
7.2.4. SCOT ANALYSIS
7.2.5. STRATEGIC ANALYSIS
7.3. QIAGEN N.V. (NETHERLANDS)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. STRATEGIC INITIATIVES 
7.3.4. SCOT ANALYSIS 
7.3.5. STRATEGIC ANALYSIS
7.4. THERMO FISHER SCIENTIFIC INC. (U.S.)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. STRATEGIC INITIATIVES 
7.4.4. SCOT ANALYSIS
7.4.5. STRATEGIC ANALYSIS
7.5. ABBOTT LABORATORIES, INC. (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. STRATEGIC INITIATIVES 
7.5.4. SCOT ANALYSIS
7.5.5. STRATEGIC ANALYSIS
7.6. MYRIAD GENETICS, INC. (U.S.)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. STRATEGIC INITIATIVES 
7.6.4. SCOT ANALYSIS 
7.6.5. STRATEGIC ANALYSIS
7.7. DANAHER CORPORATION (U.S.)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. STRATEGIC INITIATIVES 
7.7.4. SCOT ANALYSIS 
7.7.5. STRATEGIC ANALYSIS
7.8. ALMAC GROUP (U.S.)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. STRATEGIC INITIATIVES 
7.8.4. SCOT ANALYSIS 
7.8.5. STRATEGIC ANALYSIS
7.9. SYSMEX CORPORATION (JAPAN)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. STRATEGIC INITIATIVES 
7.9.4. SCOT ANALYSIS 
7.9.5. STRATEGIC ANALYSIS
7.10. GENOMIC HEALTH, INC. (U.S.)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. STRATEGIC INITIATIVES 
7.10.4. SCOT ANALYSIS 
7.10.5. STRATEGIC ANALYSIS
7.11. GE HEALTHCARE LTD(US)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. STRATEGIC INITIATIVES 
7.11.4. SCOT ANALYSIS
7.11.5. STRATEGIC ANALYSIS
7.12. LIFE TECHNOLOGIES CORPORATION (U.S.)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. STRATEGIC INITIATIVES 
7.12.4. SCOT ANALYSIS
7.12.5. STRATEGIC ANALYSIS
7.13. DANAHER CORPORATION (U.S.)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. STRATEGIC INITIATIVES 
7.13.4. SCOT ANALYSIS
7.13.5. STRATEGIC ANALYSIS
7.14. ILLUMINA, INC (U.S.)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. STRATEGIC INITIATIVES 
7.14.4. SCOT ANALYSIS
7.14.5. STRATEGIC ANALYSIS
7.15. ARUP LABORATORIES INC (U.S.)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. STRATEGIC INITIATIVES 
7.15.4. SCOT ANALYSIS
7.15.5. STRATEGIC ANALYSIS
 
LIST OF TABLES
 
1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2014-2023 ($ MILLION)
2. GLOBAL ASSAY KITS AND REAGENTS MARKET BY GEOGRAPHY 2014-2023($ MILLION)
3. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
4. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2014-2023($ MILLION)
5. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
6. GLOBAL POLYMERASE CHAIN REACTION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
8. GLOBAL NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY 2014-2023($ MILLION)
9. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
10. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION 2014-2023($ MILLION)
11. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-20232023 ($ MILLION)
12. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
13. GLOBAL INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2014-2023($ MILLION) 
14. GLOBAL OTHER INDICATIONS MARKET BY GEOGRAPHY 2014-2023($ MILLION)
15. NORTH AMERICA COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
16. EUROPE COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
17. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
18. REST OF THE COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
 
LIST OF FIGURES
 
1. GLOBAL COMPANION DIAGNOSTIC MARKET   2014-2023($ MILLION)
2. GLOBAL ASSAY KITS AND REAGENTS MARKET 2014-2023($ MILLION)
3. GLOBAL IN SITU HYBRIDIZATION MARKET 2014-2023($ MILLION)
4. GLOBAL IN SITU HYBRIDIZATION MARKET 2014-2023($ MILLION)
5. GLOBAL POLYMERASE CHAIN REACTION MARKET 2014-2023($ MILLION)
6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET 2014-2023($ MILLION)
7. GLOBAL NEXT GENERATION SEQUENCING MARKET 2014-2023($ MILLION)
8. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET 2014-2023($ MILLION)
9. GLOBAL ONCOLOGY MARKET 2014-20232023 ($ MILLION)
10. GLOBAL NEUROLOGY MARKET Y 2014-2023($ MILLION)
11. GLOBAL INFECTIOUS DISEASES MARKET 2014-2023($ MILLION) 
12. GLOBAL OTHER INDICATIONS MARKET 2014-2023($ MILLION)
13. UNITED STATES (U.S.) COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
14. CANADA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
15. UNITED KINGDOM (UK) COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
16. FRANCE COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
17. GERMANY COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
18. RUSSIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
19. ROE COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
20. INDIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
21. CHINA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
22. JAPAN COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
23. AUSTRALIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
24. ROAPAC COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
25. LATIN AMERICA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
26. MENA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 8390547755

Email: info@occamsresearch.com

 

 

Go To Top
viewthroughconversion